BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution approved in 1985 for treatment of glaucoma and ocular hypertension. It is a small-molecule beta-blocker administered as eye drops. The drug works by reducing intraocular pressure through beta-adrenergic receptor antagonism.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30%), suggesting smaller team size and focus on retention over expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BETAGAN offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Working on this product typically involves managing market share erosion, optimizing manufacturing costs, and maintaining compliance rather than driving innovation or expansion.
Brand ManagerProduct Manager
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.